Update in Food Allergy Management

New insights into the immunopathology of FA have led to development of cautious use of controlled exposure to food allergens through allergen immunotherapy and emerging use of monoclonal antibody therapy to interfere with the synthesis of immunoglobulin E (IgE). The expert faculty will contextualize the mechanisms and available clinical trial data related to the use of biologic agents in FA as monotherapy and as adjunct therapy to allergen immunotherapy.

Educational Provider 
This activity is provided by Paradigm Medical Communications, LLC.  

Supporter Acknowledgment 
This activity is supported by an educational grant from Genentech, a member of the Roche Group.  

Target Audience

This activity has been designed to address the educational needs of pediatric nurse practitioners, pediatricians, and allergists. It may also benefit other clinicians interested in the management of food allergy (FA).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the burden of FA on children and caregivers
  • Describe the immunopathology of FA and related mechanisms by which biologic agents may mediate FA
  • Summarize clinical trial safety and efficacy data related to the use of anti-IgE therapy in FA (0.25 Rx)
Course summary
Available credit: 
  • 1.00 Contact hours
Course opens: 
Course expires: 

Lauren Herlihy, DNP, APRN, CPNP
Clinical Assistant Professor
UNC Chapel Hill School of Nursing
Research Instructor
UNC Chapel Hill School of Medicine
Chapel Hill, NC

Brian P. Vickery, MD
Professor of Pediatrics
Marcus Professor of Pediatric Immunology
Chief, Division of Allergy/Immunology 
Emory University & Children’s Healthcare of Atlanta
Atlanta, GA

Disclosure of Relevant Financial Relationships
In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.

Lauren Herlihy, DNP, APRN, CPNP
Has no relevant financial relationships with ineligible companies to disclose

Brian P. Vickery, MD
Advisor: Aimmune Therapeutics; Genentech, Inc.; Novartis AG; Revolo Biotherapeutics; Sanofi; Stallergenes Greer
Research Funding: Aimmune Therapeutics; DBV Technologies; Genentech, Inc.; Novartis AG
Stocks: Moonlight Therapeutics (expired 6/23)

Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

This CE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, NAPNAP or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Terms of Use and Privacy Policy
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, NAPNAP or Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by NAPNAP or Paradigm Medical Communications, LLC. NAPNAP and Paradigm Medical Communications, LLC accept no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC and NAPNAP are committed to protecting the privacy of those who participate in the activities located at ce.napnap.org (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CE activity. All evaluative information submitted is collected and retained, and used by NAPNAP and Paradigm Medical Communications, LLC to continuously improve the learning experience.

Contact Us
If you have any questions or comments, please email us at ce@napnap.org.

© 2024 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.


This program is accredited for 1.0 NAPNAP CE contact hour, of which 0.25 hour contains pharmacology (Rx) content per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines.


Physician Accreditation Statement

   Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

To claim AMA PRA Category 1 Credit™ please complete the activity at Update in Food Allergy Management (paradigmmc.com)


Available Credit

  • 1.00 Contact hours


Please login or register to take this course.

Required Hardware/software

Hardware/Software Requirements
This accredited CE activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support
If you have any technical problems or playback issues, email us at ce@napnap.org.